Orion Pharma announces first results from Phase 1/2 TEADES trial with ODM-212 in patients with advanced solid tumours (30-May) (€71.60, 0.00)
Bayer presents primary results of Phase II ARACOG (AFT-47) head-to-head trial at ASCO; trial met its primary endpoint (€36.53, 0.00)
Orion to present its first clinical data from Phase 1/2 TEADES trial of ODM-212 at the 2026 ASCO Annual Meeting (€71.15, 0.00)
Bayer announces that Primary results from the Phase II ARASEC trial show that NUBEQA plus ADT showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with mCSPC (€37.85, -0.33)
FDA approves Tessie for noise aversion and separation anxiety in dogs (€71.00, 0.00)
StreetAccount Summary - Trading higher/lower: EU mid-morning
Transcript Intelligence: Orion Q1 Earnings Themes
Transcript Intelligence: Orion Q1 Earnings Guidance
Transcript Intelligence: Orion Q1 Earnings Q&A
Orion reports Q1 EPS €0.64 vs FactSet €0.71 [7 est, €0.62-0.96]; specifies FY26 outlook (€70.10, -3.25)
Powered by FactSet Research Systems Inc.